Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
11
GRI Quote, Financials, Valuation and Earnings
Last price:
$0.34
Seasonality move
:
-14%
Day range:
$0.34 - $0.38
52-week range:
$0.33 - $15.64
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.56x
Volume:
977K
Avg. volume:
1.1M
1-year change:
-97.29%
Market cap:
$1.1M
Revenue:
--
EPS (TTM):
-$15.73
Analysts' Opinion
-
Consensus RatingGRI Bio, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $23.00, GRI Bio, Inc. has an estimated upside of 6644.87% from its current price of $0.34.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $0.34.
Fair Value
-
According to the consensus of 2 analysts, GRI Bio, Inc. has 6644.87% upside to fair value with a price target of $23.00 per share.
GRI vs. S&P 500
-
Over the past 5 trading days, GRI Bio, Inc. has underperformed the S&P 500 by -29.85% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
GRI Bio, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
GRI Bio, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter GRI Bio, Inc. reported revenues of --.
Earnings Growth
-
GRI Bio, Inc. earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter GRI Bio, Inc. reported earnings per share of -$1.28.
Enterprise value:
-2.9M
EV / Invested capital:
-1.38x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.31x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$4K
Return On Assets:
-218.8%
Net Income Margin (TTM):
--
Return On Equity:
-395.62%
Return On Invested Capital:
-381.19%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$17K | -$18K | -$4K | -$1K | -$1K | |
| Operating Income | -$11M | -$8.3M | -$11.3M | -$2.1M | -$3.4M | |
| EBITDA | -$11M | -$8.3M | -$11.3M | -$2.1M | -$3.4M | |
| Diluted EPS | -$139,731.55 | -$51.88 | -$15.73 | -$0.67 | -$1.28 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $9.9M | $5.6M | $4.4M | $5.3M | $4.7M | |
| Total Assets | $10.1M | $5.6M | $4.4M | $5.5M | $4.8M | |
| Current Liabilities | $1.3M | $2.1M | $2.2M | $1.7M | $2.8M | |
| Total Liabilities | $1.4M | $2.1M | $2.2M | $1.8M | $2.8M | |
| Total Equity | $8.7M | $3.5M | $2.2M | $3.7M | $2M | |
| Total Debt | -- | -- | -- | $84K | $30K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$4.4M | -$12.2M | -$9.2M | -$2.3M | -$2.3M | |
| Cash From Investing | -$11K | -- | -- | -- | -- | |
| Cash From Financing | $7.8M | $13.4M | $8.5M | $661K | $1.2M | |
| Free Cash Flow | -$4.4M | -$12.2M | -$9.2M | -$2.3M | -$2.3M | |
GRI
Sector
Market Cap
$1.1M
$28.4M
Price % of 52-Week High
2.18%
51.17%
Dividend Yield
0%
0%
Shareholder Yield
-126.44%
-1.49%
1-Year Price Total Return
-97.29%
-16.67%
Beta (5-Year)
--
0.518
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.43
200-day SMA
Sell
Level
$1.97
Bollinger Bands (100)
Sell
Level
1.18 - 2.08
Chaikin Money Flow
Sell
Level
-80.2M
20-day SMA
Sell
Level
$1.28
Relative Strength Index (RSI14)
Sell
Level
20.17
ADX Line
Sell
Level
40.1
Williams %R
Buy
Level
-99.6187
50-day SMA
Sell
Level
$1.63
MACD (12, 26)
Sell
Level
-0.41
25-day Aroon Oscillator
Sell
Level
-72
On Balance Volume
Neutral
Level
35.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-10.9964)
Sell
CA Score
(Annual)
Level (-9.0348)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (14.1468)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
GRI Bio, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded by Vipin Kumar Chaturvedi in May 2009 and is headquartered in La Jolla, CA.
Stock Forecast FAQ
In the current month, GRI has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GRI average analyst price target in the past 3 months is $23.00.
-
Where Will GRI Bio, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that GRI Bio, Inc. share price will rise to $23.00 per share over the next 12 months.
-
What Do Analysts Say About GRI Bio, Inc.?
Analysts are divided on their view about GRI Bio, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that GRI Bio, Inc. is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is GRI Bio, Inc.'s Price Target?
The price target for GRI Bio, Inc. over the next 1-year time period is forecast to be $23.00 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GRI A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for GRI Bio, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GRI?
You can purchase shares of GRI Bio, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase GRI Bio, Inc. shares.
-
What Is The GRI Bio, Inc. Share Price Today?
GRI Bio, Inc. was last trading at $0.34 per share. This represents the most recent stock quote for GRI Bio, Inc.. Yesterday, GRI Bio, Inc. closed at $0.34 per share.
-
How To Buy GRI Bio, Inc. Stock Online?
In order to purchase GRI Bio, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get GRI Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
GRI
Sector
P/E ratio
--
23.89x
PEG ratio
--
-0.01x
P/B ratio
0.56x
1.81x
Price / LTM sales
--
1.58x
Growth Metrics
GRI
Sector
Revenue growth
--
4.62%
Earnings growth
-90.76%
10.7%
Revenue (5-year growth)
--
6.5%
Earnings forecast
-$1.11
-$0.21
Profitability
GRI
Sector
Profitability FY 2024
-$4K
$3.6M
Return on invested capital
-381.19%
-31.84%
Return on assets
-218.8%
-27.96%
Return on equity
-395.62%
-37.63%
Earnings Date
Last Earnings Date
Dec
23
Next Earnings Date
Dec
23
Estimated Next Earnings Date
Mar
24
Balance Sheet
GRI
Sector
Total cash
$4.1M
$26.4M
Short term investments
--
$25.7M
Total assets
$5.7M
$76.9M
Long term debt
$30K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is down 1.16% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 2.13% over the past day.
Buy
69
QBTS alert for Dec 23
D-Wave Quantum, Inc. [QBTS] is down 2.55% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
